Completed Access to Information Requests

About this information

Search the summaries of completed Access to Information (ATI) requests to find information about ATI requests made to the Government of Canada after January 2020. If you find a summary of interest, you can request a copy of the records at no cost using the form below each summary. Requests made through this form are considered informal requests and are not subject to the same requirements as requests under the Access to Information Act (ATIA).

If you don’t find what you are looking for you can request additional government records under an institution’s control by contacting the institution’s Access to Information and Privacy Coordinator or by submitting a formal access to information request.

*All information provided will incorporate the necessary exemptions and exclusions as per the Access to Information Act and the Privacy Act.

Download datasets of the summaries of completed access to information requests.

Current Search

Report Type

Organization

Disposition

Year

Month

Found 169 record(s)

Req # A-2021-000299

Briefing note in the Ministerial Executive Correspondence System (MECS) for the following file: 21-104908-893, Meeting with Thoughtwire.

Organization: Health Canada

4 page(s)
June 2021

Req # A-2020-001748

Adverse Drug Reaction (ADR). Report number: E2B_03444012.

Organization: Health Canada

62 page(s)
June 2021

Req # A-2020-001773

Adverse Drug Reaction (ADR). Report number: E2B_03498705.

Organization: Health Canada

37 page(s)
June 2021

Req # A-2020-001924

Adverse Reaction Reports (AERs) for Abilify. Report numbers: E2B_03452264, E2B_03452286, E2B_03452288, E2B_03452296, E2B_03452301, E2B_03452302, E2B_03452319, E2B_03452360, E2B_03452382, E2B_03452517, E2B_03452588, E2B_03459113, E2B_03459121, E2B_03459127, E2B_03459576.

Organization: Health Canada

185 page(s)
June 2021

Req # A-2020-001871

Adverse Drug Reaction (ADR) for Leflunomide. Report number: 000726887.

Organization: Health Canada

3 page(s)
June 2021

Req # A-2020-001878

Adverse Reaction Reports (AERs). Report numbers: E2B_03425677, E2B_03071666, E2B_03517209, E2B_03088216, E2B_03110552, E2B_03451303, E2B_03420640, E2B_03467188, E2B_03188480, E2B_03452634, E2B_03427733, E2B_03339482, E2B_03423249, E2B_03406161, E2B_03418489, E2B_03392328, E2B_03432300, E2B_03478652, E2B_03420851, E2B_03407302.

Organization: Health Canada

298 page(s)
June 2021

Req # A-2020-001876

Adverse Reaction Reports (AERs) for C1 Esterase Inhibitor (Human). Report numbers: E2B_03501587, E2B_03454679, E2B_03474145, E2B_03484753, E2B_03424986, E2B_03424957. (ADRs) for Gammagard Liquid. Report numbers: 925469, 925764.

Organization: Health Canada

86 page(s)
June 2021

Req # A-2020-001884

Adverse Reaction Reports (AERs) for Mezavant. Report numbers: 927241, E2B_03486671, E2B_03510421, 926096.

Organization: Health Canada

29 page(s)
June 2021

Req # A-2020-001604

Adverse Drug Reaction (ADR). Report number: E2B_03380048.

Organization: Health Canada

9 page(s)
June 2021

Req # A-2020-001614

Briefing note in the Ministerial Executive Correspondence System (MECS) for the following file: 20-115590-809.

Organization: Health Canada

7 page(s)
June 2021
Date modified: